Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00512902 · ClinicalTrials.gov registry record · Phase 1
A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis
A Phase 1 study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00512902 is a Phase 1 study that has completed, run by University of California, Los Angeles. The registered enrollment target is 20 participants.
The verdict
NCT00512902, a Phase 1 study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and tolerability of imatinib (gleevec) in subjects who have systemic sclerosis. Imatinib has been approved by the FDA for the treatment of newly diagnosed adult patients with CML (newly diagnosed adult patients and for the treatment of patients with an accelerated phase. Imatinib is also approved for the treatment of patients with a certain type of gastrointestinal cancer (called stromal tumors) but it has not been approved to treat systemic sclerosis. Imatinib works by interfering with an enzyme called tyrosine phosphatase resulting in suppression of the immune system. It als interferes with a protein called platelet derived growth factor receptor (PDGFr) that has been linked to increased fibrosis.
Interventions
- DRUG Imatinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2007-08 |
| Est. Completion | 2008-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00512902
The ClinicalTrials.gov registry entry for NCT00512902 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Imatinib is the first listed.
NCT00512902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00512902 about?
NCT00512902 is a clinical study titled "A Study Using The Experimental Drug Called Imatinib (Gleevec) in Subjects With Systemic Sclerosis". The purpose of this study is to assess the safety and tolerability of imatinib (gleevec) in subjects who have systemic sclerosis. Imatinib has been approved by the FDA for the treatment of newly diagnosed adult patients with CML (newly diagnosed adult patients and for the treatment of patients with ...
What is the current status of trial NCT00512902?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2007-08. Estimated completion is 2008-12.
What interventions are being tested in trial NCT00512902?
The interventions under investigation include: Imatinib (DRUG).
Who is sponsoring clinical trial NCT00512902?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.